• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma.抗PD-1/PD-L1单药疗法对肝细胞癌的疗效有限。
Liver Cancer. 2020 Dec;9(6):629-639. doi: 10.1159/000512170. Epub 2020 Oct 26.
2
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.阿替利珠单抗联合或不联合贝伐珠单抗治疗不可切除肝细胞癌（GO30140）：一项开放标签、多中心、1b 期研究。
Lancet Oncol. 2020 Jun;21(6):808-820. doi: 10.1016/S1470-2045(20)30156-X.
3
Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.免疫检查点抑制剂作为一线治疗方案，单独或联合化疗用于晚期非小细胞肺癌：一项系统评价和网络荟萃分析。
Lung Cancer. 2019 Aug;134:127-140. doi: 10.1016/j.lungcan.2019.05.029. Epub 2019 May 30.
4
New PD-L1 inhibitors in non-small cell lung cancer - impact of atezolizumab.非小细胞肺癌中的新型程序性死亡受体1配体（PD-L1）抑制剂——阿替利珠单抗的影响
Lung Cancer (Auckl). 2017 Jul 13;8:67-78. doi: 10.2147/LCTT.S113177. eCollection 2017.
5
Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives.检查点抑制剂治疗转移性胃癌的演进：现状与未来展望。
Cancer Treat Rev. 2018 May;66:104-113. doi: 10.1016/j.ctrv.2018.04.004. Epub 2018 Apr 22.
6
The New Immuno-Oncology-Based Therapies and Their Perspectives in Hepatocellular Carcinoma.基于免疫肿瘤学的新型疗法及其在肝细胞癌中的前景
Cancers (Basel). 2021 Jan 11;13(2):238. doi: 10.3390/cancers13020238.
7
Radiation improves antitumor effect of immune checkpoint inhibitor in murine hepatocellular carcinoma model.放射治疗可增强免疫检查点抑制剂在小鼠肝癌模型中的抗肿瘤效果。
Oncotarget. 2017 Jun 20;8(25):41242-41255. doi: 10.18632/oncotarget.17168.
8
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.阿替利珠单抗单药或联合贝伐珠单抗与舒尼替尼治疗肾细胞癌的临床活性和分子相关性。
Nat Med. 2018 Jun;24(6):749-757. doi: 10.1038/s41591-018-0053-3. Epub 2018 Jun 4.
9
[Immunotherapy for renal cell carcinoma - current status].[肾细胞癌的免疫疗法——现状]
Aktuelle Urol. 2018 Apr;49(2):187-191. doi: 10.1055/a-0581-4451. Epub 2018 Mar 27.
10
Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges.肝细胞癌领域中对PD-1/PD-L1检查点抑制反应的预测因素：现状与挑战
Cancers (Basel). 2019 Oct 14;11(10):1554. doi: 10.3390/cancers11101554.

引用本文的文献

1
Treatment Outcomes of Systemic Therapies for Infiltrative Hepatocellular Carcinoma.浸润性肝细胞癌全身治疗的疗效
J Hepatocell Carcinoma. 2025 Jun 23;12:1221-1229. doi: 10.2147/JHC.S528897. eCollection 2025.
2
Immunotherapy targeting liver cancer tumor-initiating cells: challenges, mechanisms, and emerging therapeutic horizons.靶向肝癌肿瘤起始细胞的免疫疗法：挑战、机制及新兴治疗前景
Front Immunol. 2025 Jun 11;16:1621243. doi: 10.3389/fimmu.2025.1621243. eCollection 2025.
3
Optimal sequencing of locoregional and systemic therapies for intermediate and advanced hepatocellular carcinoma: a network meta-analysis.中晚期肝细胞癌局部区域和全身治疗的最佳序贯：一项网状Meta分析。
J Cancer Res Clin Oncol. 2025 Jun 25;151(6):196. doi: 10.1007/s00432-025-06233-7.
4
Effectiveness and safety of angiogenesis inhibitors combined with PD-1/PD-L1 blockades in the first-line treatment of patients with advanced hepatocellular carcinoma: A single-center retrospective study.血管生成抑制剂联合PD-1/PD-L1阻断剂一线治疗晚期肝细胞癌患者的有效性和安全性：一项单中心回顾性研究。
Medicine (Baltimore). 2025 Mar 14;104(11):e41814. doi: 10.1097/MD.0000000000041814.
5
Precise In Situ Delivery of a Photo-Enhanceable Inflammasome-Activating Nanovaccine Activates Anticancer Immunity.精确原位递送光增强型炎症小体激活纳米疫苗可激活抗肿瘤免疫。
Cancer Res. 2024 Nov 15;84(22):3834-3847. doi: 10.1158/0008-5472.CAN-24-0220.
6
A comprehensive pan-cancer analysis revealing the role of ITPRIPL1 as a prognostic and immunological biomarker.一项全面的泛癌分析揭示了ITPRIPL1作为一种预后和免疫生物标志物的作用。
Front Mol Biosci. 2024 Aug 15;11:1452290. doi: 10.3389/fmolb.2024.1452290. eCollection 2024.
7
Transarterial Embolization Enhances Programmed Cell Death Ligand 1 Expression and Influences CD8T Lymphocytes Cytotoxicity in an Orthotopic Hepatocellular Carcinoma Rat Model.经导管动脉栓塞增强了原位肝癌大鼠模型中程序性细胞死亡配体 1 的表达并影响 CD8T 淋巴细胞的细胞毒性。
Cardiovasc Intervent Radiol. 2024 Oct;47(10):1372-1381. doi: 10.1007/s00270-024-03813-x. Epub 2024 Aug 5.
8
Hepatocellular Carcinoma: Beyond the Border of Advanced Stage Therapy.肝细胞癌：超越晚期治疗的边界
Cancers (Basel). 2024 May 27;16(11):2034. doi: 10.3390/cancers16112034.
9
Recurrence risk stratification of hepatocellular carcinomas based on immune gene expression and features extracted from pathological images.基于免疫基因表达和病理图像特征提取的肝细胞癌复发风险分层。
PLoS Comput Biol. 2023 Dec 29;19(12):e1011716. doi: 10.1371/journal.pcbi.1011716. eCollection 2023 Dec.
10
Therapeutic Efficacy and Safety of Lenvatinib after Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma.阿替利珠单抗联合贝伐单抗治疗不可切除肝细胞癌后使用乐伐替尼的疗效和安全性
Cancers (Basel). 2023 Nov 14;15(22):5406. doi: 10.3390/cancers15225406.

本文引用的文献

1
Gd-EOB-DTPA-MRI Could Predict WNT/β-Catenin Mutation and Resistance to Immune Checkpoint Inhibitor Therapy in Hepatocellular Carcinoma.钆塞酸二钠增强磁共振成像可预测肝细胞癌中WNT/β-连环蛋白突变及对免疫检查点抑制剂治疗的耐药性。
Liver Cancer. 2020 Sep;9(5):479-490. doi: 10.1159/000509554. Epub 2020 Aug 20.
2
Association between Genetic and Immunological Background of Hepatocellular Carcinoma and Expression of Programmed Cell Death-1.肝细胞癌的遗传和免疫背景与程序性细胞死亡蛋白-1表达之间的关联
Liver Cancer. 2020 Aug;9(4):426-439. doi: 10.1159/000506352. Epub 2020 Mar 17.
3
Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma.仑伐替尼联合帕博利珠单抗治疗不可切除肝细胞癌的 Ib 期研究。
J Clin Oncol. 2020 Sep 10;38(26):2960-2970. doi: 10.1200/JCO.20.00808. Epub 2020 Jul 27.
4
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.阿替利珠单抗联合或不联合贝伐珠单抗治疗不可切除肝细胞癌（GO30140）：一项开放标签、多中心、1b 期研究。
Lancet Oncol. 2020 Jun;21(6):808-820. doi: 10.1016/S1470-2045(20)30156-X.
5
Scientific Rationale for Combination Immunotherapy of Hepatocellular Carcinoma with Anti-PD-1/PD-L1 and Anti-CTLA-4 Antibodies.肝细胞癌抗PD-1/PD-L1和抗CTLA-4抗体联合免疫治疗的科学原理
Liver Cancer. 2019 Nov;8(6):413-426. doi: 10.1159/000503254. Epub 2019 Sep 27.
6
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.阿替利珠单抗联合贝伐珠单抗治疗不可切除肝细胞癌。
N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745.
7
Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma.晚期肝细胞癌中PD-1/PD-L1抗体与VEGF抑制剂联合免疫治疗的科学依据
Cancers (Basel). 2020 Apr 27;12(5):1089. doi: 10.3390/cancers12051089.
8
Precision pathology analysis of the development and progression of hepatocellular carcinoma: Implication for precision diagnosis of hepatocellular carcinoma.精准病理学分析肝癌的发生发展：对肝癌精准诊断的启示。
Pathol Int. 2020 Mar;70(3):140-154. doi: 10.1111/pin.12895. Epub 2020 Jan 6.
9
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial.帕博利珠单抗作为 KEYNOTE-240 中晚期肝细胞癌二线治疗的疗效：一项随机、双盲、III 期试验。
J Clin Oncol. 2020 Jan 20;38(3):193-202. doi: 10.1200/JCO.19.01307. Epub 2019 Dec 2.
10
Immuno-Oncology Therapy for Hepatocellular Carcinoma: Current Status and Ongoing Trials.肝细胞癌的免疫肿瘤学疗法：现状与正在进行的试验
Liver Cancer. 2019 Jul;8(4):221-238. doi: 10.1159/000501501. Epub 2019 Jul 9.

Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma.

作者信息

Kudo Masatoshi

机构信息

Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.

出版信息

Liver Cancer. 2020 Dec;9(6):629-639. doi: 10.1159/000512170. Epub 2020 Oct 26.

DOI:10.1159/000512170
PMID:33442537
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7768125/
Abstract
摘要